DeepMed Research

Sargramostim

Generic Name: Sargramostim

Brand Names: Leukine

Drug Type: Biotech

CAS Number: 123774-72-1

Unique Ingredient Identifier: 5TAA004E22

Background: Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.

Indication: For the treatment of cancer and bone marrow transplant

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Hematopoietic Subsyndrome of Acute Radiation Syndrome, Hodgkin's Lymphoma, Neutropenia, Non-Hodgkin's Lymphoma (NHL), Severe Infection

Associated Therapies: Allogenic bone marrow transplantation therapy, Autologous bone marrow transplantation therapy, Autologous peripheral haematopoietic stem cell transplant

Clinical Trials

Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis

Phase 3

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Schering-Plough

Registration Number: NCT00002070

Locations: 🇺🇸
Children's Hosp of San Francisco, San Francisco, California, United States
🇺🇸
Pacific Presbyterian, San Francisco, California, United States
🇺🇸
Dr Douglas Dieterich, New York, New York, United States

and more 11 locations

A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia

Phase 1

Completed

Conditions: HIV Infections
Cytopenias

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Sandoz

Registration Number: NCT00002009

Locations: 🇺🇸
Beth Israel Deaconess - West Campus, Boston, Massachusetts, United States
🇺🇸
UCLA CARE Ctr, Los Angeles, California, United States

A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia

Not Applicable

Completed

Conditions: HIV Infections
Cytopenias

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Sandoz

Registration Number: NCT00002007

Locations: 🇺🇸
Natl Cancer Institute, Bethesda, Maryland, United States

A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT00000896

Locations: 🇺🇸
Ucsd, Avrc Crs, San Diego, California, United States
🇺🇸
University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸
Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States

A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine

Not Applicable

Completed

Conditions: HIV Infections
Cytopenias

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Sandoz

Registration Number: NCT00002263

Locations: 🇺🇸
Natl Cancer Institute / HIV / AIDS Malignancy Branch, Bethesda, Maryland, United States

A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma

Phase 1

Completed

Conditions: HIV Infections
Sarcoma, Kaposi

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 18

Registration Number: NCT00000694

Locations: 🇺🇸
Mem Sloan - Kettering Cancer Ctr, New York, New York, United States

The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS

Not Applicable

Completed

Conditions: HIV Infections
Cytomegalovirus Retinitis

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 50

Registration Number: NCT00000989

Locations: 🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸
Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering Cancer Ctr., New York, New York, United States

and more 1 locations

Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma

Phase 1

Completed

Conditions: Lymphoma, Non-Hodgkin
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 18

Registration Number: NCT00000689

Locations: 🇺🇸
USC CRS, Los Angeles, California, United States

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT00001090

Locations: 🇺🇸
UAB AVEG, Birmingham, Alabama, United States
🇺🇸
Univ. of Rochester AVEG, Rochester, New York, United States
🇺🇸
JHU AVEG, Baltimore, Maryland, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy